Skip to main content
Watch Insiders
URGNHealthcare

UroGen Pharma Ltd (URGN) Insider Trading

In the last 90 days, 3 UroGen Pharma Ltd (URGN) insiders reported no open-market purchases and 4 sales totaling $3,037,646. Source: SEC Form 4 filings.

SEC-reported filing activity is provided for research purposes and is not investment advice.

90-day C-suite buyers
0
90-day purchase value
$0.00
Corporate buyers
0
Latest transaction
Oct 8, 2026

Executive filings

Open-market transaction history

Purchase and sale summaries are ordered by the latest reported transaction date.

Open-market insider purchase and sale transactions
DateInsider nameRoleTypeSharesPriceTotal value
Oct 8, 2026Chris DegnanChief Financial OfficerSale2,202$36.69$80,791
Sep 8, 2026Mark SchoenbergChief Medical OfficerSale871$42.92$37,383
Sep 8, 2026Jason Drew SmithGeneral CounselSale1,519$42.54$64,618
Aug 20, 2026Mark SchoenbergChief Medical OfficerSale60,677$47.05$2,854,853
Jul 9, 2026Mark SchoenbergChief Medical OfficerSale10,000$40.00$400,000
Jun 22, 2026Mark SchoenbergChief Medical OfficerSale10,000$35.01$350,100
Jun 8, 2026Mark SchoenbergChief Medical OfficerSale5,222$27.30$142,561
May 8, 2026Mark SchoenbergChief Medical OfficerSale10,000$30.00$300,000

Common questions

URGN insider trading FAQ

Are URGN insiders buying or selling?
Over the last 90 days, URGN insiders were net sellers, reporting $0.00 of open-market purchases and $3,037,646 of sales.
When was the last URGN insider purchase?
No open-market insider purchase of UroGen Pharma Ltd stock was reported in the last 90 days.
Where does URGN insider trading data come from?
Watch Insiders reads the SEC Form 4 filings that UroGen Pharma Ltd officers, directors, and 10% owners submit to EDGAR, and refreshes this page daily.